These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

983 related articles for article (PubMed ID: 23233156)

  • 1. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
    Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
    Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors.
    Bischoff M; Bischoff G; Buck A; von Baer A; Pauls S; Scheffold F; Schultheiss M; Gebhard F; Reske SN
    Arch Orthop Trauma Surg; 2010 Jul; 130(7):819-27. PubMed ID: 19636577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
    Bredella MA; Caputo GR; Steinbach LS
    AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas.
    Iagaru A; Quon A; McDougall IR; Gambhir SS
    Clin Nucl Med; 2006 Dec; 31(12):754-60. PubMed ID: 17117068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.
    Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE
    Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
    Du Y; Cullum I; Illidge TM; Ell PJ
    J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.
    Liu FY; Yen TC; Chen MY; Lai CH; Chang TC; Chou HH; Hong JH; Chen YR; Ng KK
    Cancer; 2009 Dec; 115(23):5470-80. PubMed ID: 19739235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of combined positron emission tomography and computed tomography in thymoma recurrence.
    El-Bawab HY; Abouzied MM; Rafay MA; Hajjar WM; Saleh WM; Alkattan KM
    Interact Cardiovasc Thorac Surg; 2010 Oct; 11(4):395-9. PubMed ID: 20639307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
    Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
    Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
    Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
    Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of (18)F-FDG PET/CT in postoperative monitoring for patients with colorectal carcinoma.
    Han A; Xue J; Zhu D; Zheng J; Yue J; Yu J
    Cancer Epidemiol; 2011 Oct; 35(5):497-500. PubMed ID: 21296635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
    Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
    Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
    Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
    Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.